Arbutus to Participate in Two Upcoming Investor Conferences
03 9월 2024 - 8:30PM
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the
“Company”), a clinical-stage biopharmaceutical company leveraging
its extensive virology expertise to develop a functional cure for
people with chronic hepatitis B virus (cHBV) infection, today
announced that the Arbutus management team will participate in and
host one-on-one meetings at the following two upcoming investor
conferences which are being held in New York:
- H.C. Wainwright
26th Annual Global Investment
Conference: Formal Presentation on September 9, 2024 at
8:00 am ET
- Baird Global Healthcare
Conference: Fireside Chat on September 10, 2024 at 8:30 am
ET
To access the live webcast of the presentation
and fireside chat please visit:
https://investor.arbutusbio.com/events-presentations. An archived
replay of the webcast will be available on the Arbutus website for
a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics with distinct
mechanisms of action, which can potentially be combined to provide
a functional cure for patients with chronic hepatitis B virus
(cHBV). We believe the key to success in developing a functional
cure involves suppressing HBV DNA, reducing surface antigen, and
boosting HBV-specific immune responses. Our pipeline of internally
developed, proprietary compounds includes an RNAi therapeutic,
imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran
has generated meaningful clinical data demonstrating an impact on
both surface antigen reduction and reawakening of the HBV-specific
immune response. Imdusiran is currently in two Phase 2a combination
clinical trials. AB-101 is currently being evaluated in a Phase
1a/1b clinical trial. For more information, visit
www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor RelationsPhone:
215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Arbutus Biopharma (NASDAQ:ABUS)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024